Table 1 |.
Glioma cell state heterogeneity drives distinct mechanisms of network communication which informs potential therapeutic strategies
Glioma type | Cell state resemblance | Network interactions | Molecular mechanisms and therapeutic targets | Clinically available drugs that impact glioma preclinical models |
---|---|---|---|---|
Paediatric low-grade | OPC, astrocyte161 | Paracrineb, neuronal hyperexcitabilityb | NLGN3b, HCNb | ADAM10 inhibitorsb, lamotrigineb |
IDH and H3 wild-type high-grade glioma | OPC, astrocyte, MES, NPC87 | Neuron–glioma synapse, tumour microtube, neuronal hyperexcitability, paracrine, hub cells (also called pacemaker or oscillatory cells) | AMPAR, potassium channels, CX43, NLGN3, KCa, TSP1, IGF1 | Perampanel, meclofenamate, senicapoc, gabapentin, ADAM10 inhibitors |
IDH-mutant astrocytoma | NPC and OPC, astrocyte, oligodendrocyte85 | Neuron–glioma synapse, tumour microtube, neuronal hyperexcitability | AMPAR, CX43 | Perampanelc, meclofenamatec |
IDH-mutant oligodendroglioma | NPC and OPC, astrocyte, oligodendrocyte85,162 | Paracrine, neuronal hyperexcitability | NLGN3 | ADAM10 inhibitorsc |
H3 G34R/V-mutant DHG | INPC, NPC, astrocyte152 | Unknown | Unknown | Unknown |
H3 K27M-mutant DMG | OPC, astrocyte, oligodendrocyte, MESa,86,163 | Neuron–glioma synapse, tumour microtube, neuronal hyperexcitability, paracrine, hub cells | AMPAR, potassium channels, CX43, NLGN3 | Perampanel, meclofenamate, ADAM10 inhibitors, senicapocc, gabapentinc |
ADAM10, a disintegrin and metalloproteinase domain-containing protein 10; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CX43, connexin 43; DHG, diffuse hemispheric glioma; DMG, diffuse midline glioma; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; IGF1, insulin-like growth factor 1; INPC, interneuron progenitor cell; MES, mesenchymal cell; NLGN3, neuroligin 3; KCa, calcium-activated potassium channel; NPC, neural precursor cell; OPC, oligodendrocyte precursor cell; TSP1, thrombospondin 1.
Chiefly in older patients.
Studied in neurofibromatosis type 1 (NF1)-associated low-grade optic gliomas.
Drug mechanism has been identified but the drugs have not yet been tested in that specific glioma type.